Method of using vasoconstrictive agents during energy-based tissue therapy
A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.
1. A surgical technique, comprising the steps of:
administering at least one adenosine receptor antagonist to a patient; and
performing an energy-based therapy to form a coagulation zone, wherein the at least one adenosine receptor antagonist is administered in an amount from about 0.1 to about 200 nmol/min/kg.
2. A surgical technique in accordance with claim 1 , wherein the step of performing an energy-based therapy further comprises ablating tissue.
3. A surgical technique in accordance with claim 1 , wherein the energy-based therapy comprises cardiac ablation, transmyocardial revascularization, benign prostate hyperplasia therapy, ablation of endometriosis, breast cancer treatment, hemostasis, vessel sealing, endometrial ablation, skin resurfacing, metastasis ablation, image-guided treatments, noninvasive blood flow monitoring, surgical tissue welding, tissue reshaping, laser therapy, microwave therapy, radiofrequency therapy, high-intensity focused ultrasound therapy, cryotherapy therapy, conductive heating, or combinations thereof.
4. A surgical technique in accordance with claim 1 , wherein the coagulation zone is formed after heating with an RF electrode and administrating at least one vasoconstrictive agent.
5. A surgical technique in accordance with claim 1 , wherein the energy based therapy produces a coagulation zone having a radius.
6. A surgical technique in accordance with claim 5 , wherein the radius has a length of about 1 cm to about 10 cm.
7. A surgical technique in accordance with claim 5 , wherein the radius is greater than 1 cm.
8. A surgical technique in accordance with claim 1 , wherein the coagulation zone has a diameter of about 2 cm to about 20 cm.
9. A surgical technique in accordance with claim 1 , wherein the at least one adenosine receptor antagonist is administered simultaneously to performing the energy-based therapy in an amount effective to prevent or minimize local vasodilation.
10. A surgical technique in accordance with claim 1 , wherein in vivo, the at least one adenosine receptor antagonist binds to at least one adenosine receptor.
11. A surgical technique in accordance with claim 1 , wherein the at least one adenosine receptor antagonist is administered in a pharmaceutical composition that includes a pharmaceutically acceptable carrier or diluent.
12. A surgical technique in accordance with claim 1 , wherein the at least one adenosine receptor antagonist is at least one A1 adenosine receptor antagonist.
13. A surgical technique in accordance with claim 12 , wherein the at least one A1 adenosine receptor antagonist is selected from the group consisting of 1,3-dipropyl-8-cyclopentylxanthine, 8-(4-[({[(2-aminoethyl)amino]carbonyl)oxy]-phenyl} -1,3-dipropylxanthine, N(6)-Endonorbornan-2-yl-9-methyladenine, ((S)-(−)-8-(3-Oxocyclopentyl)-1,3- dipropyl-7H-purine-2,6-dione), (3- [(4 -amino)phenethyl]-8-cyclopentylexanthine, 1,3-dipropyl-8-(dicyclopropylmethyl)xanthine, and combinations thereof.
14. A surgical technique in accordance with claim 1 , wherein the administering step includes treatment of symptoms associated with adenosine including tumor cell proliferation.
15. A surgical technique in accordance with claim 1 , wherein the administering step includes administering the adenosine receptor antagonist immediately adjacent to tissue being treated.